title: Leukemic T cells from patients with cutaneous T-cell lymphoma demonstrate enhanced activation through CDw60, CD2, and CD28 relative to activation through the T-cell antigen receptor complex.
abstract: Antigen-dependent activation of T cells occurs through the T-cell antigen-receptor complex (TCR/CD3). Antigen-independent T-cell activation may occur through the surface molecules CDw60, CD2, and CD28. We wished to determine whether these antigen-independent T-cell-activation pathways could be involved in proliferation of leukemic T cells from patients with cutaneous T-cell lymphoma (CTCL). Whereas CDw60 was only expressed on 28% +/- 7% (mean +/- SEM) of blood T cells obtained from healthy control subjects (n = 4), CDw60 was expressed on 94% +/- 3% of blood T cells obtained from patients with CTCL (n = 4). Dual color immunofluorescence microscopy of the T-cell infiltrate in involved skin of these patients demonstrated that almost 100% of the T cells expressed CDw60. Not only did T cells in the patients with CTCL express CDw60, but triggering of the T cells with anti-CDw60 resulted in enhanced proliferation relative to anti-TCR/CD3 and mitogenic lectins. Other antigen-independent pathways also appeared highly active in the T cells from patients with CTCL because enhanced proliferation relative to anti-TCR/CD3 or mitogenic lectins was found when anti-CD2 or anti-CD28 plus phorbol ester was used as stimulant. Despite the brisk proliferation induced by anti-CDw60, anti-CD2, or anti-CD28, T cells from the patients did not produce detectable amounts of gamma-interferon. The inability to produce gamma-interferon correlates with our finding of absent (n = 3) or weak (n = 1) intercellular adhesion molecule-1 expression in the lesional keratinocytes in these patients. In conclusion, T cells of patients with CTCL demonstrate elevated expression of a T-cell-independent signaling molecule CDw60 and respond to antigen-independent activating signals.
authors.affiliation: Department of Dermatology, Gentofte Hospital, University of Copenhagen, Denmark.
authors.forename: E R
authors.initials: ER
authors.lastname: Hansen
authors.forename: G L
authors.initials: GL
authors.lastname: Vejlsgaard
authors.forename: K D
authors.initials: KD
authors.lastname: Cooper
authors.forename: M
authors.initials: M
authors.lastname: Heidenheim
authors.forename: J K
authors.initials: JK
authors.lastname: Larsen
authors.forename: V C
authors.initials: VC
authors.lastname: Ho
authors.forename: C W
authors.initials: CW
authors.lastname: Ross
authors.forename: D A
authors.initials: DA
authors.lastname: Fox
authors.forename: K
authors.initials: K
authors.lastname: Thomsen
authors.forename: O
authors.initials: O
authors.lastname: Baadsgaard
mesh_terms: D000368:Aged; D015703:Antigens, CD / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D018801:CD2 Antigens; D018106:CD28 Antigens; D006801:Humans; D007371:Interferon-gamma / Q000378:metabolism; D007938:Leukemia / Q000473:pathology*; D008213:Lymphocyte Activation; D016399:Lymphoma, T-Cell / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D011948:Receptors, Antigen, T-Cell / Q000276:immunology*; D011971:Receptors, Immunologic / Q000276:immunology; D012878:Skin Neoplasms / Q000378:metabolism / Q000473:pathology*; D013601:T-Lymphocytes / Q000378:metabolism / Q000473:pathology*
chemical_list: D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D018106:CD28 Antigens; C064741:CDw60 antigen; D011948:Receptors, Antigen, T-Cell; D011971:Receptors, Immunologic; D007371:Interferon-gamma